Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 nivolumab + ipilimumab + chemotherapy in advanced NSCLC patients with HIV, HBV, HCV, or PASC
2022-002313-41Phase 2Terminated
- Sponsor
- Centro Ricerche Cliniche di Verona Srl
- Start
- Feb 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab, pemetrexed, carboplatin, cisplatin and 1 more in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma, sponsored by Centro Ricerche Cliniche di Verona Srl. Primary endpoints: Grade 3 or 4 treatment-related adverse events and Objective response rate. Started Feb 2023; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2022-002313-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002313-41.